BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1322@pharmaconomics
DTSTAMP:20260707T015842Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:MESO PDUFA — Rexlemestrocel-L (estimated date)
DESCRIPTION:The FDA's approval decision on Rexlemestrocel-L for Chronic low back pain is due ~ Mar 31\, 2028. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1345099/000134509926000029/exhibit992h12026results.htm\n\nTrack it: https://pharmaconomics.com/e/1322
URL:https://pharmaconomics.com/e/1322
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MESO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR